Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children
- 1.5k Downloads
Clinical trials in children are being encouraged by regulatory authorities in light of the immense off-label and unlicensed use of drugs in the paediatric population. The use of in silico techniques for pharmacokinetic prediction will aid in the development of paediatric clinical trials by guiding dosing regimens, ensuring efficient blood sampling times, maximising therapeutic effect and potentially reducing the number of children required for the study. The goal of this study was to extend an existing physiologically based pharmacokinetic (PBPK) model for adults to reflect the age-related physiological changes in children from birth to 18 years of age and, in conjunction with a previously developed age-specific clearance model, to evaluate the accuracy of the paediatric PBPK model to predict paediatric plasma profiles.
The age-dependence of bodyweight, height, organ weights, blood flows, interstitial space and vascular space were taken from the literature. Physiological parameters that were used in the PBPK model were checked against literature values to ensure consistency. These included cardiac output, portal vein flow, extracellular water, total body water, lipid and protein. Five model compounds (paracetamol [acetaminophen], alfentanil, morphine, theophylline and levofloxacin) were then examined by gathering the plasma concentration-time profiles, volumes of distribution and elimination half-lives from different ages of children and adults. First, the adult data were used to ensure accurate prediction of pharmacokinetic profiles. The model was then scaled to the specific age of children in the study, including the scaling of clearance, and the generated plasma concentration profiles, volumes of distribution and elimination half-lives were compared with literature values.
Physiological scaling produced highly age-dependent cardiac output, portal vein flow, extracellular water, total body water, lipid and protein values that well represented literature data. The pharmacokinetic profiles in children for the five compounds were well predicted and the trends associated with age were evident. Thus, young neonates had plasma concentrations greater than the adults and older children had concentrations less than the adults. Eighty-three percent, 97% and 87% of the predicted plasma concentrations, volumes of distribution and elimination half-lives, respectively, were within 50% of the study reported values. There was no age-dependent bias for term neonates to 18 years of age when examining volumes of distribution and elimination half-lives.
This study suggests that the developed paediatric PBPK model can be used to scale pharmacokinetics from adults. The accurate prediction of pharmacokinetic parameters in children will aid in the development of dosing regimens and sampling times, thus increasing the efficiency of paediatric clinical trials.
KeywordsLevofloxacin Alfentanil PBPK Model Total Body Water Term Neonate
No specific funding was received for this project. All authors are employed by Bayer Technology Services (BTS) GmbH.
- 1.Best Pharmaceuticals for Children Act, January 4, 2002 (Public Law No. 107–109). USA 2005Google Scholar
- 20.PK-Sim® software manual [online]. Available from URL: http://www.pk-sim.com [Accessed 2006 August 21]
- 21.Syracuse Research Corporation. SRC PhysProp database [online]. Available from URL: http://www.syrres.com/esc/phys-demo.htm [Accessed 2005 Aug 10]
- 23.Hardman JG, Limbird LE, Gilman A. Goodman and Gilman’s: the pharmacological basis of therapeutics. 10th ed. New York: McGraw Hill, 2001Google Scholar
- 28.Dobashi A. Levofloxacin. Department of Pharmaceutical Information Science, Tokyo University of Pharmacy and Life Science [online]. Available from URL: http://www.pharmis.org/database/structure/l_group/levofloxacin.html [Accessed 2005 Aug 23]
- 30.International Commission on Radiological Protection (ICRP). Basic anatomical and physiological data for use in radiological protection: reference values. ICRP publication 89. Amsterdam: Elsevier Science, 2002Google Scholar
- 33.Raynaud C, Chiron C, Maziere B, et al. Followup of regional CBF in children from birth to 18 years with Xe-133 [abstract]. J Nucl Med 1990; 31S: 892Google Scholar
- 38.Raitakari M, Nuutila P, Ruotsalainen U, et al. Evidence for dissociation of insulin stimulation of blood flow and glucose uptake in human skeletal muscle: studies using [15O]H2O, [18F]fluoro-2-deoxy-D-glucose, and positron emission tomography. Diabetes 1996; 45(11): 1471–7PubMedCrossRefGoogle Scholar
- 48.Lopez Barrio AM, De Palma Gaston MA, Munoz Conde J. Evaluation of the portal blood flow in healthy children by doppler duplex echography. An Esp Pediatr 1996; 44(1): 45–9Google Scholar
- 50.Winso O, Biber B, Gustavsson B, et al. Portal blood flow in man during graded positive end-expiratory pressure ventilation. Intensive Care Med 1985; 12(2): 80–8Google Scholar
- 62.Dickerson JWT, Widdowson EM. Chemical changes in skeletal muscle during development. Biochemistry 1960; 74: 247–57Google Scholar
- 67.Friss-Hansen B. Water distribution in the foetus and newborn infant. Acta Paediatr Scand 1983; 305(S): 1–7Google Scholar
- 73.Zeigler EE, O’Donnell AM, Nelson SE, et al. Body composition of the reference fetus. Growth 1976; 40(4): 329–41Google Scholar
- 84.Holford NHG, Hale M, Ko HC, et al., editors. Simulation in drug development: good practices. San Francisco (CA): Center for Drug Development Science, University of California San Francisco, 1999Google Scholar
- 86.Boyd E. The growth of the surface area of the human body. Minneapolis: The University of Minnesota Press, 1935Google Scholar